Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulindac
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and relieve symptoms of arthritis, including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gout. It works by inhibiting the production of prostaglandins, which cause pain, fever, and inflammation. Sulindac is also used for conditions like bursitis and tendinitis. It is a prodrug that is metabolized into an active sulfide compound in the body.
- Brand names
- Clinoril
- Other names
- sulindac
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on sulindac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulindac.